Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SAR408701 versus docetaxel in previously treated CEACAM5-positive metastatic non-squamous non-small cell lung cancer
2019-001273-81Phase 3Active
- Sponsor
- Sanofi
- Start
- Oct 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing SAR408701 with Docetaxel (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Oct 2019; status: active.
02
Drugs
tusamitamab ravtansinedocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2019-001273-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001273-81.